Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis

Taymaa May; Marcus Bernardini; Stephanie Lheureux; Katja K.H. Aben; Elisa V. Bandera; Matthias W. Beckmann; Javier Benitez; Andrew Berchuck; Line Bjørge; Michael E. Carney; Daniel W. Cramer; Anna Defazio; Thilo Dörk; Diana M. Eccles; Michael Friedlander; María Jose García; Ellen L. Goode; Alexander Hein; Allan Jensen; Sharon Johnatty; Catherine J. Kennedy; Lambertus A. Kiemeney; Susanne K. Kjær; Jolanta Kupryjanczyk; Keitaro Matsuo; Valerie McGuire; Francesmary Modugno; Lisa E. Paddock; Tanja Pejovic; Catherine M. Phelan; Marjorie J. Riggan; Cristina Rodriguez-Antona; Joseph H. Rothstein; Weiva Sieh; Honglin Song; Kathryn L. Terry; Anne M.Van Altena; Adriaan Vanderstichele; Ignace Vergote; Liv Cecilie Vestrheim Thomsen; Penelope M. Webb; Nicolas Wentzensen; Lynne R. Wilkens; Argyrios Ziogas; Haiyan Jiang; Alicia Tone

doi:10.1503/cjs.017020

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis

Taymaa May, Marcus Bernardini, Stephanie Lheureux, Katja K.H. Aben, Elisa V. Bandera, Matthias W. Beckmann, Javier Benitez, Andrew Berchuck, Line Bjørge, Michael E. Carney, Daniel W. Cramer, Anna Defazio, Thilo Dörk, Diana M. Eccles, Michael Friedlander, María Jose García, Ellen L. Goode, Alexander Hein, Allan Jensen, Sharon JohnattyCatherine J. Kennedy, Lambertus A. Kiemeney, Susanne K. Kjær, Jolanta Kupryjanczyk, Keitaro Matsuo, Valerie McGuire, Francesmary Modugno, Lisa E. Paddock, Tanja Pejovic, Catherine M. Phelan, Marjorie J. Riggan, Cristina Rodriguez-Antona, Joseph H. Rothstein, Weiva Sieh, Honglin Song, Kathryn L. Terry, Anne M.Van Altena, Adriaan Vanderstichele, Ignace Vergote, Liv Cecilie Vestrheim Thomsen, Penelope M. Webb, Nicolas Wentzensen, Lynne R. Wilkens, Argyrios Ziogas, Haiyan Jiang, Alicia Tone

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. Methods: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves. Results: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. Conclusion: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

Original language	English (US)
Pages (from-to)	E310-E320
Journal	CMAJ
Volume	66
Issue number	3
DOIs	https://doi.org/10.1503/cjs.017020
State	Published - Jun 2023

ASJC Scopus subject areas

General Medicine

Access to Document

10.1503/cjs.017020

Cite this

May, T., Bernardini, M., Lheureux, S., Aben, K. K. H., Bandera, E. V., Beckmann, M. W., Benitez, J., Berchuck, A., Bjørge, L., Carney, M. E., Cramer, D. W., Defazio, A., Dörk, T., Eccles, D. M., Friedlander, M., García, M. J., Goode, E. L., Hein, A., Jensen, A., ... Tone, A. (2023). Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis. CMAJ, 66(3), E310-E320. https://doi.org/10.1503/cjs.017020

May, T, Bernardini, M, Lheureux, S, Aben, KKH, Bandera, EV, Beckmann, MW, Benitez, J, Berchuck, A, Bjørge, L, Carney, ME, Cramer, DW, Defazio, A, Dörk, T, Eccles, DM, Friedlander, M, García, MJ, Goode, EL, Hein, A, Jensen, A, Johnatty, S, Kennedy, CJ, Kiemeney, LA, Kjær, SK, Kupryjanczyk, J, Matsuo, K, McGuire, V, Modugno, F, Paddock, LE, Pejovic, T, Phelan, CM, Riggan, MJ, Rodriguez-Antona, C, Rothstein, JH, Sieh, W, Song, H, Terry, KL, Altena, AMV, Vanderstichele, A, Vergote, I, Thomsen, LCV, Webb, PM, Wentzensen, N, Wilkens, LR, Ziogas, A, Jiang, H & Tone, A 2023, 'Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis', CMAJ, vol. 66, no. 3, pp. E310-E320. https://doi.org/10.1503/cjs.017020

@article{8b67a0c39b334d8ca6f155ced437390d,

title = "Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis",

abstract = "Background: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. Methods: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves. Results: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. Conclusion: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.",

author = "Taymaa May and Marcus Bernardini and Stephanie Lheureux and Aben, {Katja K.H.} and Bandera, {Elisa V.} and Beckmann, {Matthias W.} and Javier Benitez and Andrew Berchuck and Line Bj{\o}rge and Carney, {Michael E.} and Cramer, {Daniel W.} and Anna Defazio and Thilo D{\"o}rk and Eccles, {Diana M.} and Michael Friedlander and Garc{\'i}a, {Mar{\'i}a Jose} and Goode, {Ellen L.} and Alexander Hein and Allan Jensen and Sharon Johnatty and Kennedy, {Catherine J.} and Kiemeney, {Lambertus A.} and Kj{\ae}r, {Susanne K.} and Jolanta Kupryjanczyk and Keitaro Matsuo and Valerie McGuire and Francesmary Modugno and Paddock, {Lisa E.} and Tanja Pejovic and Phelan, {Catherine M.} and Riggan, {Marjorie J.} and Cristina Rodriguez-Antona and Rothstein, {Joseph H.} and Weiva Sieh and Honglin Song and Terry, {Kathryn L.} and Altena, {Anne M.Van} and Adriaan Vanderstichele and Ignace Vergote and Thomsen, {Liv Cecilie Vestrheim} and Webb, {Penelope M.} and Nicolas Wentzensen and Wilkens, {Lynne R.} and Argyrios Ziogas and Haiyan Jiang and Alicia Tone",

year = "2023",

month = jun,

doi = "10.1503/cjs.017020",

language = "English (US)",

volume = "66",

pages = "E310--E320",

journal = "CMAJ",

issn = "0820-3946",

publisher = "Canadian Medical Association",

number = "3",

}

TY - JOUR

T1 - Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma

T2 - An international multicentre analysis

AU - May, Taymaa

AU - Bernardini, Marcus

AU - Lheureux, Stephanie

AU - Aben, Katja K.H.

AU - Bandera, Elisa V.

AU - Beckmann, Matthias W.

AU - Benitez, Javier

AU - Berchuck, Andrew

AU - Bjørge, Line

AU - Carney, Michael E.

AU - Cramer, Daniel W.

AU - Defazio, Anna

AU - Dörk, Thilo

AU - Eccles, Diana M.

AU - Friedlander, Michael

AU - García, María Jose

AU - Goode, Ellen L.

AU - Hein, Alexander

AU - Jensen, Allan

AU - Johnatty, Sharon

AU - Kennedy, Catherine J.

AU - Kiemeney, Lambertus A.

AU - Kjær, Susanne K.

AU - Kupryjanczyk, Jolanta

AU - Matsuo, Keitaro

AU - McGuire, Valerie

AU - Modugno, Francesmary

AU - Paddock, Lisa E.

AU - Pejovic, Tanja

AU - Phelan, Catherine M.

AU - Riggan, Marjorie J.

AU - Rodriguez-Antona, Cristina

AU - Rothstein, Joseph H.

AU - Sieh, Weiva

AU - Song, Honglin

AU - Terry, Kathryn L.

AU - Altena, Anne M.Van

AU - Vanderstichele, Adriaan

AU - Vergote, Ignace

AU - Thomsen, Liv Cecilie Vestrheim

AU - Webb, Penelope M.

AU - Wentzensen, Nicolas

AU - Wilkens, Lynne R.

AU - Ziogas, Argyrios

AU - Jiang, Haiyan

AU - Tone, Alicia

PY - 2023/6

Y1 - 2023/6

N2 - Background: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. Methods: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves. Results: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. Conclusion: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

AB - Background: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. Methods: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves. Results: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. Conclusion: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

UR - http://www.scopus.com/inward/record.url?scp=85166274935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85166274935&partnerID=8YFLogxK

U2 - 10.1503/cjs.017020

DO - 10.1503/cjs.017020

M3 - Article

AN - SCOPUS:85166274935

SN - 0820-3946

VL - 66

SP - E310-E320

JO - CMAJ

JF - CMAJ

IS - 3

ER -

Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this